

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 59733

Manuscript Type: CASE REPORT

Clinical cure and liver fibrosis reversal after postoperative antiviral combination therapy in hepatitis B-associated non-cirrhotic hepatocellular carcinoma: A case report

Xue-Ping Yu, Qi Lin, Zhi-Peng Huang, Wei-Shan Chen, Ming-Hui Zheng, Yi-Juan Zheng, Ju-Lan Li, Zhi-Jun Su

Abstract

BACKGROUND

The incidence of hepatocellular carcinoma (HCC) is high in China, and approximately

Match Overview

1

Internet 66 words
crawled on 23-Jul-2020
www.wjgnet.com

3%

2

Internet 27 words
crawled on 13-Nov-2020
www.researchsquare.com

1%

3

Internet 17 words
crawled on 11-Aug-2019
www.dovepress.com

1%

Clinical cure and liver fibrosis reversal after postoperative antiviral c



ALL

IMAGES

VIDEOS

12,900 Results

Any time ▾

[Antiviral therapy leads to histological improvement of ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480175>

Fig. 3 shows a **case** of cirrhosis with regression of **fibrosis** and architectural improvement **after** long-term **antiviral therapy**. Figure 3 Representative areas of **liver** biopsy specimens, obtained from a 51-year-old chronic **hepatitis B** patient before initiation of treatment (A,B) and **after** 8 ...

Cited by: 11

Author: Nikolaos Papachrysos, Prodromos Hytiogl...

Publish Year: 2015

[Cost-effectiveness of new antiviral treatments for non ...](#)

<https://gh.bmj.com/content/5/11/e003194> ▾

Nov 27, 2020 · The primary aim of HCV infection treatment is to achieve sustained virologic response (SVR), which can significantly reduce the risk of progression to **liver** cirrhosis or **hepatocellular carcinoma**.⁵ Pegylated interferon plus ribavirin (PEG-RBV) was the standard of care in China before the introduction of direct-acting antivirals (DAAs) in 2017.⁶ ...

[APASL consensus statements and recommendations for ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003900>

May 26, 2016 · Acute assessment of **liver fibrosis** is of **clinical** importance in decision-making, especially in the era of DAA and IFN-free regimens. Patients with cirrhosis with or without other unfavorable factors, such as HCV GT-1a, HCV GT-3, and prior null responses, require intensified treatment [188–191]. Although **liver** biopsy remains the gold standard ...

Cited by: 71

Author: Masao Omata, Tatsuo Kanda, Lai Wei, Min...

Publish Year: 2016

[Long-Term Outcome After Antiviral Therapy of Patients With ...](#)

<https://www.researchgate.net/publication/49624011...>

Sustained virological response can reduce all-cause mortality and the incidence of **hepatocellular carcinoma** of patients with **hepatitis C**. Advanced **liver fibrosis** is still a risk factor for the ...

[Assessment of Drug-Induced Liver Injury \(DILI\) in Clinical ...](#)

<https://link.springer.com/article/10.1007/s40264-020-01014-2> ▾

Nov 03, 2020 · With the widespread development of new drugs to treat chronic **liver** diseases (CLDs), including viral **hepatitis** and nonalcoholic steatohepatitis (NASH), more patients are entering trials with abnormal baseline **liver** tests and with advanced **liver** injury including cirrhosis. The current regulatory

ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

13,100 Results

Any time ▾

[Antiviral therapy leads to histological improvement of ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480175>

Fig. 3 shows a **case** of cirrhosis with regression of **fibrosis** and architectural improvement **after** long-term **antiviral therapy**. Figure 3 Representative areas of **liver** biopsy specimens, obtained from a 51-year-old chronic **hepatitis B** patient before initiation of treatment (A,B) and **after** 8 ...

Cited by: 11

Author: Nikolaos Papachrysos, Prodromos Hytiogl...

Publish Year: 2015

[Long-Term Outcome After Antiviral Therapy of Patients With ...](#)

<https://www.researchgate.net/publication/49624011...>

Sustained virological response can reduce all-cause mortality and the incidence of **hepatocellular carcinoma** of patients with **hepatitis C**. Advanced **liver fibrosis** is still a risk factor for the ...

[APASL consensus statements and recommendations for ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003900>

May 26, 2016 · Acute assessment of **liver fibrosis** is of **clinical** importance in decision-making, especially in the era of DAA and IFN-free regimens. Patients with cirrhosis with or without other unfavorable factors, such as HCV GT-1a, HCV GT-3, and prior null responses, require intensified treatment [188–191]. Although **liver** biopsy remains the gold standard ...

Cited by: 71

Author: Masao Omata, Tatsuo Kanda, Lai Wei, Min...

Publish Year: 2016

[Assessment of Drug-Induced Liver Injury \(DILI\) in Clinical ...](#)

<https://link.springer.com/article/10.1007/s40264-020-01014-2> ▾

Nov 03, 2020 · With the widespread development of new drugs to treat chronic **liver** diseases (CLDs), including viral **hepatitis** and nonalcoholic steatohepatitis (NASH), more patients are entering trials with abnormal baseline **liver** tests and with advanced **liver** injury, including cirrhosis. The current regulatory guidelines addressing the monitoring, diagnosis, and management of suspected drug-induced **liver** ...